Abstract
Neonatal diethylstilbestrol (DES) exposure elicits a wide range of abnormalities in the female mouse genital tract. This animal model system is suitable for investigating the mechanism of DES syndrome in humans. Accumulated evidence has shown that critical periods in development are present for distinct and permanent alterations in the female genital tract of mice exposed to DES neonatally (DES-mice). These effects of DES and other estrogens are mainly mediated by estrogen receptor α (ERα) through multiple pathways. Induction of ERα by DES exposure in neonatal stromal and epithelial cells, and successive premature activation of estrogen-regulated genes are thought to be essential to induce the abnormalities. Induction of malformation, permanent changes in estrogen-regulated genes, such as protooncogenes and growth factors, and carcinogenesis are assumed to be interdependent. This review focuses the following topics to discuss the molecular basis of DES-induced abnormalities mainly based on the results by histochemical techniques in the uterus: spatiotemporal expression of ERa and coactivators, proteins relating morphogenesis, and estrogen-regulated protooncogenes and growth factors.
Keywords: Growth factors, Protooncogenes, Hox, Wnt, Angiogenesis, Estrogen receptors, Female reproductive tract, Diethylstilbestrol
Current Pharmaceutical Design
Title: Expression of Estrogen-Regulated Genes During Development in the Mouse Uterus Exposed to Diethylstilbestrol Neonatally
Volume: 12 Issue: 12
Author(s): Shuji Yamashita
Affiliation:
Keywords: Growth factors, Protooncogenes, Hox, Wnt, Angiogenesis, Estrogen receptors, Female reproductive tract, Diethylstilbestrol
Abstract: Neonatal diethylstilbestrol (DES) exposure elicits a wide range of abnormalities in the female mouse genital tract. This animal model system is suitable for investigating the mechanism of DES syndrome in humans. Accumulated evidence has shown that critical periods in development are present for distinct and permanent alterations in the female genital tract of mice exposed to DES neonatally (DES-mice). These effects of DES and other estrogens are mainly mediated by estrogen receptor α (ERα) through multiple pathways. Induction of ERα by DES exposure in neonatal stromal and epithelial cells, and successive premature activation of estrogen-regulated genes are thought to be essential to induce the abnormalities. Induction of malformation, permanent changes in estrogen-regulated genes, such as protooncogenes and growth factors, and carcinogenesis are assumed to be interdependent. This review focuses the following topics to discuss the molecular basis of DES-induced abnormalities mainly based on the results by histochemical techniques in the uterus: spatiotemporal expression of ERa and coactivators, proteins relating morphogenesis, and estrogen-regulated protooncogenes and growth factors.
Export Options
About this article
Cite this article as:
Yamashita Shuji, Expression of Estrogen-Regulated Genes During Development in the Mouse Uterus Exposed to Diethylstilbestrol Neonatally, Current Pharmaceutical Design 2006; 12 (12) . https://dx.doi.org/10.2174/138161206776389840
DOI https://dx.doi.org/10.2174/138161206776389840 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Herbal Medicine for Slowing Aging and Aging-associated Conditions: Efficacy, Mechanisms and Safety
Current Vascular Pharmacology Bypass Mechanisms of Resistance to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukaemia
Current Drug Discovery Technologies Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and Treatment
Current Gene Therapy Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer
Current Cancer Therapy Reviews Patient Radiation Doses in Interventional Cardiology Procedures
Current Cardiology Reviews Cancer-Specific Ligands Identified from Screening of Peptide-Display Libraries
Current Pharmaceutical Design Stem Cells and Translational Medicine: From Research to Clinical Procedures
Current Tissue Engineering (Discontinued) Recent Progress of Src Family Kinase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Virulence Factors of Helicobacter pylori: Practical Biomarkers
Recent Patents on Biomarkers Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets DNA Damage and Epigenetic Changes in Kidney Diseases - Focused on Transcription Factors in Podocytes
Current Hypertension Reviews Clioquinol – A Novel Copper-Dependent and Independent Proteasome Inhibitor
Current Cancer Drug Targets Radiolabelled Peptides: Eon in Radiopharmaceutical
Current Radiopharmaceuticals Anticancer Drugs Discovery and Development from Marine Organisms
Current Topics in Medicinal Chemistry Recent Patents on Thiazole Derivatives Endowed with Antitumor Activity
Recent Patents on Anti-Cancer Drug Discovery Animal Models for the Evaluation of Theranostic Radiopharmaceuticals
Current Radiopharmaceuticals Toll-Like Receptors: Cost or Benefit for Cancer?
Current Pharmaceutical Design Mammaglobin-Based Strategies for Treatment of Breast Cancer
Current Cancer Drug Targets DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AML
Current Pharmaceutical Biotechnology Proteasome as an Emerging Therapeutic Target in Cancer
Current Pharmaceutical Design